Neurocrine Biosciences, Inc. (NBIX)
156.22
-0.35
(-0.22%)
USD |
NASDAQ |
Sep 11, 16:00
156.04
-0.18
(-0.12%)
After-Hours: 20:00
Neurocrine Biosciences Price to Book Value : 4.297 for Sept. 11, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 4.297 |
| September 10, 2026 | 4.307 |
| September 09, 2026 | 4.267 |
| September 08, 2026 | 4.267 |
| September 04, 2026 | 4.281 |
| September 03, 2026 | 4.356 |
| September 02, 2026 | 4.340 |
| September 01, 2026 | 4.312 |
| August 31, 2026 | 4.237 |
| August 28, 2026 | 4.238 |
| August 27, 2026 | 4.289 |
| August 26, 2026 | 4.307 |
| August 25, 2026 | 4.219 |
| August 24, 2026 | 4.210 |
| August 21, 2026 | 4.197 |
| August 20, 2026 | 4.207 |
| August 19, 2026 | 4.278 |
| August 18, 2026 | 4.242 |
| August 17, 2026 | 4.250 |
| August 14, 2026 | 4.201 |
| August 13, 2026 | 4.149 |
| August 12, 2026 | 4.305 |
| August 11, 2026 | 4.454 |
| August 10, 2026 | 4.536 |
| August 07, 2026 | 4.495 |
| Date | Value |
|---|---|
| August 06, 2026 | 4.396 |
| August 05, 2026 | 4.442 |
| August 04, 2026 | 4.568 |
| August 03, 2026 | 4.572 |
| July 31, 2026 | 4.588 |
| July 30, 2026 | 5.103 |
| July 29, 2026 | 4.973 |
| July 28, 2026 | 5.029 |
| July 27, 2026 | 4.852 |
| July 24, 2026 | 4.835 |
| July 23, 2026 | 4.790 |
| July 22, 2026 | 4.750 |
| July 21, 2026 | 4.925 |
| July 20, 2026 | 4.759 |
| July 17, 2026 | 4.700 |
| July 16, 2026 | 4.719 |
| July 15, 2026 | 4.733 |
| July 14, 2026 | 4.732 |
| July 13, 2026 | 4.789 |
| July 10, 2026 | 4.872 |
| July 09, 2026 | 4.966 |
| July 08, 2026 | 4.903 |
| July 07, 2026 | 4.882 |
| July 06, 2026 | 4.789 |
| July 02, 2026 | 4.793 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amarin Corp. Plc | 0.6533 |
| Liquidia Corp. | 30.48 |
| BioCryst Pharmaceuticals, Inc. | -- |
| Halozyme Therapeutics, Inc. | 85.17 |
| Iovance Biotherapeutics, Inc. | 5.293 |
Price to Book Value Related Metrics
| PE Ratio | 22.89 |
| PS Ratio | 4.79 |
| PEG Ratio | 0.2255 |
| Price to Free Cash Flow | 19.90 |
| Price | 156.22 |
| Earnings Yield | 4.37% |
| Market Cap | 15.87B |
| PEGY Ratio | 0.2255 |
| Operating PE Ratio | 20.05 |
| Normalized PE Ratio | 23.35 |